NCT00077987已完成2 期
A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 84
- 主要终点
- Anti-tumor efficacy
研究概览
简要总结
Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Metastatic colorectal cancer
- •Failed selected cancer therapies in the past.
排除标准
- •Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than bevacizumab.
结局指标
主要结局
Anti-tumor efficacy
次要结局
- Tumor control survival safety
研究者
相似试验
已完成
2 期
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.Breast NeoplasmsNCT00078000Pfizer64
已完成
2 期
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00092001Pfizer111
终止
2 期
Efficacy of SU 011248 in Head And Neck CarcinomaRecurrent DiseaseSquamous Cell Head and Neck CarcinomaPalliative TreatmentNCT00408252Cliniques universitaires Saint-Luc- Université Catholique de Louvain54
已完成
2 期
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal TumorGastrointestinal Stromal TumorsNCT00137449Pfizer60
已完成
2 期
Treatment With SU11248 in Patients With Neuroendocrine TumorsNeuroendocrine TumorsNCT00056693Pfizer107